View Entire Collection
By Clinical Topic
By State Requirement
Diabetes – Summer 2012
Future of Nursing Initiative
Heart Failure - Fall 2011
Influenza - Winter 2011
Nursing Ethics - Fall 2011
Trauma - Fall 2010
Traumatic Brain Injury - Fall 2010
Fluids & Electrolytes
MONDAY, Oct. 3 (HealthDay News) -- Treatment of localized prostate cancer using intensity modulated radiation therapy (IMRT) is associated with a considerable reduction in late bowel and rectal side effects and significantly decreased rectal and bladder toxicity compared to three-dimensional conformal radiation therapy (3D-CRT), according to a study presented the annual meeting of the American Society for Radiation Oncology, held from Oct. 2 to 6 in Miami Beach.
Jeff Michalski, M.D., from Washington University Medical Center in St. Louis, and colleagues conducted a dose-escalation trial to investigate the acute and late toxicities associated with high-dose radiation therapy. A cohort of 748 men with localized prostate cancer randomized to treatment in the high-dose arm were allocated to treatment with 3D-CRT or IMRT. Toxicities were classified from grade zero (no toxicity) to four (severe toxicity). Patient characteristics correlating with toxicity were assessed.
The investigators found that IMRT treatment correlated with a significant decrease in acute grade 2+ rectal/bowel and urinary toxicity and a 26 percent reduction in late grade 2+ rectal and bowel side effects. White men had a significantly (15 percent) increased risk of rectal side effects compared to other races, irrespective of radiation treatment.
"This study supports the continued use of IMRT in the management of prostate cancer. It is a safe and very well-tolerated therapy, with fewer complications than 3D-CRT," Michalski said in a statement.
Sign up for our free enewsletters to stay up-to-date in your area of practice - or take a look at an archive of prior issues
Join our CESaver program to earn up to 100 contact hours for only $34.95
Explore a world of online resources
Back to Top